British drug discovery and development company Aptamer Group have launched their new biomarker discovery service, Optimer biomarker discovery. The service uses proteomics analysis for high-throughput biomarker identification integrated with the company’s established Optimer platform to generate corresponding affinity ligands.
Optimers are the group’s proprietary aptamer format which have been optimised for enhanced stability and binding specificity. Aptamer owns a suite of Optimer libraries for therapeutic, diagnostic, or research applications.
“Our biomarker discovery service addresses a fundamental challenge in life sciences research, which is the need for faster, more efficient identification of clinically relevant molecular targets,” said Aptamer CEO, Arron Tolley.
He continued: “By combining our Optimer libraries with proteomic capabilities, we can deliver validated biomarkers alongside functional binding tools, significantly accelerating the translation from discovery to application.
The company says that its new service has research applications in multiple areas including target identification, biomarker validation, diagnostic marker discovery, companion diagnostic development, and resistance marker identification.
Aptamer says on its website that “Using Optimer biomarker discovery, disease states reveal their own targets, allowing you to reveal what is completely invisible to target-first thinking and get to the right biomarker faster.”
Tolley commented: “The strong interest we've received from pharmaceutical and biotechnology partners demonstrates the value of this integrated approach.”